CARDIOPROTECTIVE EFFECT OF TRIPLE THERAPY FOR HYPERTENSION
- Authors: Khafizova L.1, Khamidullaeva G.1
-
Affiliations:
- Republican Specialized Center of Cardiology
- Issue: Vol 28, No 3 (2017)
- Pages: 76-79
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116832
- ID: 116832
Cite item
Open Access
Access granted
Abstract
Analysis of three-component therapy with amlodipine, indapamide, and renin-angiotensin system blockers allows it to be considered as optimal in reducing the risk of cardiovascular events in most hypertensive patients.
Full Text
About the authors
L. Khafizova
Republican Specialized Center of CardiologyCandidate of Medical Sciences
G. Khamidullaeva
Republican Specialized Center of Cardiology
Email: gulnoz0566@mail.ru
MD
References
- The MRFIT research group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results // JAMA. - 1982; 248: 1465-77.
- Диагностика и лечение артериальной гипертензии. Рекомендации ВНОК (третий пересмотр) // Кардиоваск. тер. и профилакт. - 2008; 7 (Прил. 2): 31.
- Sesso H., Rosner M., Hennekens C. et al. Systolic and diastolic blood pressure, pulse pressure and mean arterial pressure as predictors of cardiovascular disease risk in men // Hypertension. - 2000; 36: 801-7.
- Шляхто Е.В., Кондри А.О. Структурно-функциональные изменения миокарда у больных гипертонической болезнью // Кардиология. - 1999; 6: 78-82.
- Хафизова Л.Ш., Хамидуллаева Г.А. Влияние трехмесячной комбинированной терапии индапамида с лерканидипином на параметры внутрисердечной гемодинамики // Центрально-Азиатский медицинский журнал. - 2014; том 20 (4): 271-5.
- Aznaouridis K., Stamatelopoulos K.S, Karatzis E. et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients // J. Hum. Hypertens. - 2007; 21: 654-63.
- Hansson L., Zanchetti A. The Hypertension Optimal Treatment study (The HOT Study) - patient characteristics: randomization, risk profiles, and early blood pressure results // Blood Press. - 1994; 3: 322-7.
- Грачев А.В. Центральные и периферические механизмы адаптации сердечно-сосудистой системы у больных артериальной гипертонией (патогенетические и терапевтические аспекты). Дис.. д-ра мед. наук. Ташкент, 2001; 364 с.
- The Task Force for the Management of Arterial Hypertension of the ESH and ESC // J. Hypertens. - 2013; 31 (7): 1281-357.
- Savage D., Garrison R., Kannel W. et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study // Circulation. -1987; 75: 26.
- Borgi C., Morbini M., Cicero A. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine // J. Cardiovasc. Med. - 2015; 16.
- Kalman Toth on behalf of PIANIST investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study // Am. J. Cardiovasc. Drugs. - 2014; 14: 137-45.
- Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlortiazide for hypertension in high risk patients // N. Engl. J. Med. - 2008; 359: 2417-28.
- Fagard R., Cells H., Thijs L. et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies // Hypertension. - 2009; 54: 1084-91.
- Devereux R., Wachtell K., Gerdts E. et al. Prognostic significance of left ventricular mass change during treatment of hypertension // JAMA. - 2004; 292: 2350-6.
- Dahlof B., Devereux R., Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study // Hypertension. - 1998; 32: 989-97.
Supplementary files
